ДАБИГАТРАНА ЭТЕКСИЛАТ - НОВЫЙ ПЕРОРАЛЬНЫЙ АНТИКОАГУЛЯНТ ДЛЯ ЛЕЧЕНИЯ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ

1. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb. Haemost., 2000, 83: 657-660.

2. Spencer FA, Emery C, Lessard D et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med., 2006, 21: 722-727.

3. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th еd.). Chest, 2008, 133 (Suppl.): 454S-545S.

4. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010, 4 (1): 4–37.

5. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th еd.). Chest, 2008, 133 (Suppl.): 160S-198S.

6. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy, 2008, 28: 1354-1373.

7. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost., 2007, 5: 2178-2185.

8. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet, 2007, 370: 949-956.

9. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 361: 1139-1151.

10. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009, 361: 2342-2352.

11. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost., 2005, 3: 692-694.

12. Gross PL, Weitz JI. New antithrombotic drugs. Clin. Pharmacol. Ther., 2009, 86: 139-146.

13. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practice. J. Thromb. Haemost., 2008, 6: 1647-1654.

14. Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA, 2005, 293: 681-689.

15. Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med., 2003, 349: 1713-1721.

16. Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol., 2007, 100: 1419-1426.

17. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med., 2010, 363: 2499-2510.

18. The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N. Engl. J. Med., 2012, 366: 1287-1297.

19. Agnelli G, Buller HR, Cohen A et al. AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N. Engl. J. Med., 2013, 369: 799-808.